PMID- 27659525
OWN - NLM
STAT- MEDLINE
DCOM- 20180221
LR  - 20181113
IS  - 1949-2553 (Electronic)
IS  - 1949-2553 (Linking)
VI  - 7
IP  - 43
DP  - 2016 Oct 25
TI  - A dose increased once-weekly bortezomib-based combination therapy for multiple 
      myeloma.
PG  - 70168-70174
LID - 10.18632/oncotarget.12162 [doi]
AB  - BACKGROUND: The purpose of the current study was to evaluate the efficacy and 
      safety of a dose increased weekly Bortezomib (Bor) based combination therapy in 
      multiple myeloma (MM) patients. RESULTS: The overall response rate (ORR) in the 
      modified Bor group was 76.6%, composed of 40% complete response (CR), 3.3% very 
      good partial response (VGPR) and 33.3% partial response (PR). The ORR was 82.3%, 
      with 26.5% CR, 5.9% VGPR and 50% PR in control. A subgroup analysis showed both 
      groups had equal efficacy in newly diagnosed MM patients ( P = 1.000). The median 
      progression free survival was 16 (11.7-20.3) months for the modified Bor group 
      and 12 (10.5-13.5) months for the control (P = 0.503), and the median overall 
      survival was 36 (9.4-62.6) vs 28 (21.6-34.4) months (P = 0.759). The incidences 
      of AEs were similar except grade 1-4 peripheral neuropathy (PN) rate was 10% in 
      modified regime group and 32.4% in control (P = 0.038). MATERIALS AND METHODS: 
      This was a monocentric, prospective, non-randomized, phase IV, non-inferiority 
      trial. Thirty MM patients were treated with modified Bor-based combination 
      therapy (Bor 1.6 mg/m2 on day 1, 8), with 34 MM patients on conventional 
      Bor-based combination therapy (1.3 mg/m2 on day 1, 4, 8, 11) as control. The 
      responses and adverse events (AEs) were compared. CONCLUSIONS: The increased-dose 
      weekly Bor-based combination therapies were not inferior to conventional ones in 
      terms of response and survival benefit, but showed lower rate of peripheral 
      neuropathy (PN).
FAU - Wei, Daolin
AU  - Wei D
AD  - Department of Hematology, Shanghai General Hospital, School of Medicine, Shanghai 
      Jiao Tong University, Shanghai, 200080, China.
FAU - Tong, Yin
AU  - Tong Y
AD  - Department of Hematology, Shanghai General Hospital, School of Medicine, Shanghai 
      Jiao Tong University, Shanghai, 200080, China.
FAU - Bai, Haitao
AU  - Bai H
AD  - Department of Hematology, Shanghai General Hospital, School of Medicine, Shanghai 
      Jiao Tong University, Shanghai, 200080, China.
FAU - Cai, Qi
AU  - Cai Q
AD  - Department of Hematology, Shanghai General Hospital, School of Medicine, Shanghai 
      Jiao Tong University, Shanghai, 200080, China.
FAU - Gao, Yanrong
AU  - Gao Y
AD  - Department of Hematology, Shanghai General Hospital, School of Medicine, Shanghai 
      Jiao Tong University, Shanghai, 200080, China.
FAU - Wang, Chun
AU  - Wang C
AD  - Department of Hematology, Shanghai General Hospital, School of Medicine, Shanghai 
      Jiao Tong University, Shanghai, 200080, China.
LA  - eng
PT  - Clinical Trial, Phase IV
PT  - Journal Article
PL  - United States
TA  - Oncotarget
JT  - Oncotarget
JID - 101532965
RN  - 69G8BD63PP (Bortezomib)
SB  - IM
MH  - Adult
MH  - Aged
MH  - Aged, 80 and over
MH  - Antineoplastic Combined Chemotherapy Protocols/*therapeutic use
MH  - Bortezomib/*administration & dosage/adverse effects
MH  - Female
MH  - Humans
MH  - Male
MH  - Middle Aged
MH  - Multiple Myeloma/*drug therapy/mortality
MH  - Peripheral Nervous System Diseases/chemically induced
MH  - Prospective Studies
PMC - PMC5342543
OTO - NOTNLM
OT  - adverse event
OT  - bortezomib
OT  - multiple myeloma
OT  - response rate
COIS- CONFLICTS OF INTEREST The authors declare no competing financial interests.
EDAT- 2016/09/24 06:00
MHDA- 2018/02/22 06:00
PMCR- 2016/10/25
CRDT- 2016/09/24 06:00
PHST- 2016/04/21 00:00 [received]
PHST- 2016/09/14 00:00 [accepted]
PHST- 2016/09/24 06:00 [pubmed]
PHST- 2018/02/22 06:00 [medline]
PHST- 2016/09/24 06:00 [entrez]
PHST- 2016/10/25 00:00 [pmc-release]
AID - 12162 [pii]
AID - 10.18632/oncotarget.12162 [doi]
PST - ppublish
SO  - Oncotarget. 2016 Oct 25;7(43):70168-70174. doi: 10.18632/oncotarget.12162.